ArticleCost effectiveness and resource allocation : C/E2018

Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective.

Timo Purmonen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.